Position of anticholinergic drugs in the treatment of childhood asthma

Srpski Arhiv za Celokupno Lekarstvo

Volumn 138, Issue 5-6, 2010, Pages 379-386

  Stojković Andjelković, Andjelka ^a   Obradović, Slobodan ^a   Vuletić, Biljana ^a   Radlović, Vladimir ^b  

^a Clinical Centre   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Anticholinergics; Bronchial asthma; Infants

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT;

ARTICLE; ASTHMA; CHILD; HUMAN; PATHOPHYSIOLOGY;

ASTHMA; CHILD; CHOLINERGIC ANTAGONISTS; HUMANS;

EID: 77956005112     PISSN: 03708179     EISSN: None     Source Type: Journal    
DOI: 10.2298/SARH1006379S     Document Type: Article

References (24)

1. Gross NJ. Anticholinergic Therapy in Obstructive Airways Disease. London: Franklin Scientific Publications; 1993.
2. Camargo CA Jr. Update on acute asthma. J Asthma. 2009; 46(Suppl 1):3-9.
3. Fryer AD, Costello RW, Jacoby DB. Muscarinic receptor dysfunction in asthma. ACI Int. 2000; 12(2):63-67.
4. Rodrigo GJ, Rodrigo C. First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department. Am J Respir Crit Care Med. 2000; 161:1862-1868.
5. Kunkel G. New soft mist inhaler effective in asthma drug delivery. Respiration. 2000; 7:306-314.
6. Craven D. Ipratropium not helpful in children hospitalized for asthma. J Pediatr. 2001; 138:51-58.
7. Djordjevic D, Zivkovic D, Stankovic I, Pejcic T, Ristic L, Ciric Z, et al. Is there any point in treatment of patients with chronic obstructive pulmonary diseases with salmeterol and ipratropium bromid, alone and in combination. Eur Respir J. 2002; 20(Suppl 38):245.
8. Kemp PJ. Clinician's Manual on Pediatric Asthma. London: Science Press; 2002.
9. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. NHLBI/WHO Workshop Report, 2002.
10. Parkin PC. Ipratropium no help in pediatric asthma exacerbation. Arch Pediatr Adolesc Med. 2001; 155:1329-1334.
11. Rodrigo GJ, Rodrigo C. Triple inhaled drug protocol for the treatment of acute severe asthma. Chest. 2003; 123(6):1908-1915.
12. Astra Zeneca News. FDA approves pediatric formulation of albuterol. May 7, 2001.
13. Hansen EF, Vestbo J, Phanareth K, Kok-Jensen A, Dirksen A. Peak flow as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 163:690-693.
14. Godfrey S, Barnes JP. Asthma and Wheezing in Children. London: Martin Dunitz; 1997.
15. Stojković-Andelković A. Lečenje akutnog pogoršanja astme kod dece. In: Grupa autora. Hitna stanja u medicini. Kragujevac: Medicinski fakultet Univerziteta u Kragujevcu; 2006. p.626-630.
16. Stojković-Andelković A. Lečenje akutnog pogoršanja astme kod dece. In: Urgentna stanja u pedijatriji. Kragujevac: Medicinski fakultet Univerziteta u Kragujevcu; 2002. p.21-24.
17. Stojković-Andelković A. Akutna respiratorna insuficijencija. In: Urgentna stanja u pedijatriji. Kragujevac: Medicinski fakultet Univerziteta u Kragujevcu; 2002; p.25-28.
18. Stojković-Andelković A. Prevencija vizing bronhitisa i bronhijalne astme kod dece. Acta Medica Pediatrica. 1998; 2(1):213-228.
19. Browne GJ, Trieu L, van Asperen P. Randomized, double-blind, placebo-controlled trial of intravenous salbutamol and nebulized ipratropium bromide in early management of severe acute asthma in children presenting to an emergency department. Crit Care Med. 2002; 30(2):448-453.
20. Gern J, Busse W. Contemporary Diagnosis and Managment of Allergic Diseases and Asthma. Newtown, PA: Handbooks in Health Care Company. 2009.
21. Busse WW, Holgate TS. Asthma and Rhinitis. Massachusetts, USA: Blackwell Science; 1995.
22. Naclerio RM, Pinto J, Assanasen P, Baroody FM. Observations on the ability of the nose to warm and humidify inspired air. Rhinology. 2007; 45:102-111.
23. Oga T. Salbutamol, ipratropium suitable as first-line agents for COPD. Chest. 2003; 123:1810-1816.
24. Calverley MA, Hadcroft J. Conventional bronchodilator testing of limited value in COPD evaluation. Thorax. 2001; 56:713-720.